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Gastric cancer is an important problem and is worldwide one of
the most frequently-diagnosed cancers [1, 2]. Although the
incidence of gastric cancer has been declining in the last decades,
gastric cancer still accounts for approximately 10% of all cancers
and is responsible for approximately 12% of all cancer deaths
[3]. The incidence of gastric cancer varies substantially among
racial and ethnic groups and is the highest in Japan, Korea,
Eastern Asia, Eastern Europe, and parts of Latin America.
Western Europe, the USA and other industrialised nations have
relatively low incidences.
Surgical resection remains the primary curative treatment
option in gastric cancer, with 5-year survival rates of 58%–78%
and 34% reported for stage I and II disease, respectively [4].
Despite this, the overall 5 year survival rate for all patients
remains poor and ranges between 15 and 38%. Recurrences are
frequent after surgery. Recurrence rate and subsequent survival
is dependent on the stage at diagnosis. Treatment decisions are
usually made in reference to the staging systems of the American
Joint Committee on Cancer (AJCC) and the international
Union Against Cancer (UICC) [5, 6].
Recently new data focussing on the extent of gastric resection
and on the additional treatment pre-, post- or perioperatively
have become available and give hope for improved outcome for
patients with gastric cancer.
This article reports on an expert discussion on the (neo-)
adjuvant treatment of gastric cancer. The expert discussion was
organised during the seventh World Congress on
Gastrointestinal Cancer in June 2005 in Barcelona, Spain. Well
known opinion leaders and experts from different nationalities
participated in the discussion. In preparation of this expert
discussion a detailed survey and questionnaire was sent to all
experts and the questions, answers and conclusions were
rediscussed during the meeting.
The article reports on the evidence based conclusions and
advises on the (neo-)adjuvant treatment of gastric cancer as
proposed by these experts.
staging algorithm
Most patients with gastric cancer have at an early stage mild or
no symptoms. The main reason for late diagnosis is that patients
typically present with vague and non-specific symptoms.
Upper gastrointestinal endoscopy with biopsies for histologic
confirmation is the procedure of choice for the diagnosis of
gastric cancer. Although the accuracy of the histologic diagnosis
increases with the number of biopsies, histologic confirmation
may sometimes be difficult in some cases of diffuse carcinoma,
as the intramucosal component may be small in comparison
with an extensive and mural involvement [1].
The primary staging of gastric cancer includes:
• A thorough physical examination with the search for
pathological lymph nodes. A special attention to the
supraclavicular lymph nodes (Virchow’s lymph node) is
required.
• Biochemical tests. They do not contribute to the diagnosis of
gastric cancer, although blood counts, liver and renal function
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not been found to be useful in the diagnosis of gastric cancer,
but CEA and CA 19.9, in particular, are elevated in 30–40%
of patients with primary gastric cancer. Significantly higher
levels of CEA and CA 19.9 have been found in patients with
more advanced disease. Although there are no data that prove
the use of CEA and CA 19.9 in the surveillance of gastric
cancer, the determination of these markers may be more
useful in the monitoring of gastric cancer than in the
primary diagnosis.
• Endoscopic ultrasound is useful for the local staging of
tumours at the gastro-oesophageal junction and for small
tumours and is most reliable for T-staging [7].
• A good quality CT scan of the abdomen (including pelvis) and
chest are required for the evaluation of locoregional extension
and of metastases.
For the secondary staging specific procedures can be required.
• There is no evidence for routinely performing a FDG-PET
scan in all patients. FDG-PET scanning can, however,
contribute to the detection and/or diagnosis of metastases.
The sensitivity of FDG-PET in gastric cancer is lower than in
the tumours localised at the gastro-oesophageal junction (GE-
junction) [8]. In GE-junction tumours FDG-PET scan can
give additional information and may be more conclusive
compared to good quality conventional imaging [9].
• Barium X-ray has only a limited role and does not contribute
in the staging, but may suggest a diagnosis of gastric cancer
in case of diffuse gastric cancers in which mucosal biopsies
do not confirm the suspicion of malignancy. Barium X-ray is
more useful in the preoperative evaluation and planning of
GE-junction tumours than in more distally located tumours.
• MRI imaging may replace CT scan only in selected patients
and should not be performed routinely in the staging of
gastric cancer.
• Bone scintigraphy and bone marrow aspiration should not
be performed routinely in the staging of gastric cancer.
• A diagnostic laparoscopy can be recommended if a neo-
adjuvant treatment is considered, especially in the case of a T3
or T4 and subdiaphragmatic tumour. In addition to the
diagnostic laparoscopy a peritoneal lavage can be useful in
staging. A peritoneal lavage containing malignant cells
worsens the prognosis of patients with gastric cancer. A
positive peritoneal lavage, however, does not exclude surgical
resection of the gastric cancer, but implies that an extensive
lymph-adenectomy is not useful.
treatment of gastric cancer
Important data have recently been published that led to
increased knowledge in the treatment of gastric cancer, esp. in
relation to the adjuvant and neo-adjuvant treatment of gastric
cancer. Guidelines for treatment are therefore adjusted
according to results of these important trials. Further research
remains, however, important because gastric cancer has still
a high mortality rate and less than 50% of the patients can be
treated with a R0 resection. The prognosis of metastatic gastric
cancer is poor, a median survival of 3 to 4 months for untreated
patients and 6 to 9 months for patients treated with
chemotherapy. The only potentially curative treatment for
gastric cancer is surgery. However, relapse after surgical
resection is common and accounts for the high mortality rate.
The poor survival after surgery for patients who had lymph node
metastases suggests that surgery alone is not adequate and that
an additional therapy is needed. Strategies of peri-operative
chemotherapy and of postoperative chemoradiotherapy have
shown to improve the overall survival of patients with gastric
cancer.
A multidisciplinary discussion and treatment planning of all
patients with gastric cancer is mandatory to guarantee optimal
quality of care.
surgery
Surgical resection of the primary tumour and regional lymph
nodes is the treatment of choice for gastric cancer. Surgery
should be performed by well trained and experienced surgeons
in centres of excellence to optimise the treatment planning and
the surgical treatment. Quality control of surgery and of
pathology is also very important.
For tumours located in the proximal and middle third of the
stomach or when a diffuse type gastric cancer is found a total
gastrectomy is recommended [1, 2, 10]. For tumours localised
in the distal (antral) stomach, most surgeons recommend today
a distal gastrectomy, since randomised trials did not show any
advantage of total gastrectomy over subtotal gastrectomy in this
setting [11–13]. For tumours involving the GE junction a partial
oesophagectomy should also be performed.
In very small and superficial cancers an endoscopic mucosal
resection can be performed by experienced physicians [14]. A
limited gastric resection in combination with a sentinel node
examination gives adequate locoregional control and good
chances of survival for T1 tumours in the hands of very
experienced surgeons.
Guidelines for the standardisation of surgical treatment and
pathologic evaluation have been made [10, 15]. According to
these guidelines 16 different lymph node compartments are
identified surrounding the stomach. The perigastric lymph node
stations along the lesser and greater curvature are group N1,
whereas the nodes along the left gastric, hepatic, celiac and
splenic arteries are group N2. Other lymph node stations are
described as N3 and N4 and include nodes at the posterior
aspect of the pancreas head, nodes at the root of the
mesenterium, nodes in the mesocolon of the transverse colon
and para-aortic nodes.
A D1 dissection entails removal of the involved part of the
stomach including greater and lesser omentum. For a D2
dissection, the omental bursa is removed with the front leave of
the transverse mesocolon and the mentioned vascular pedicles
of the stomach are cleared completely [10, 15]. The experts
agreed that at least a D1 resection should be performed and that
it is mandatory that at least 15 lymph nodes are removed and
recovered. The resection margins should be free of tumour. A
splenectomy and pancreas tail resection should not be
performed routinely unless there is tumour invasion (Table 1).
The experts base their recommendations on data from
different publications. In Japan complete removal of the N1 and
N2 nodes is considered standard practice for curative resection
based on evidence from large retrospective studies [16].
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Available trials in Western countries comparing D2 and D1
lymphadenectomies have failed to support extended lymph
node dissection. Several prospective randomized trials have
evaluated the role of D1 or D2 resection in the management of
gastric cancer and they did not show any advantage in terms of
overall survival in favor of D2 lymphadenectomy [12, 17–20]. In
the British trial the 5-year survival rates were 35% for D1 and
33% for D2 dissections [18]. Postoperative complications were
significantly higher in the D2 group [18]. The DGC trial in the
Netherlands randomized 996 patients between D1 and D2
lymph node dissection (380 with D1 and 331 with D2; 285
required palliative treatment). D2 resection had a higher
postoperative mortality and significantly more complications
leading to prolonged hospitalisation. At the medium follow-up
of 11 years the survival rate for D1 was 30% and D2 35% (NS).
The risk for relapse was not significantly different [10, 19]. If
hospital deaths are excluded, survival rates are 32% for D1 and
39% for D2 (NS). The relapse risk of these patients tends to be in
favor of D2 resection (P = 0.07) [10, 19]. In a recently reported
relatively small Chinese trial patients were randomised between
D1 and D3 surgery. The overall 5-year survival was significantly
higher in patients assigned to D3 surgery than in those assigned
to D1 surgery (59.5% versus 53.6%; log-rank P = 0.041) [20].
(neo-)adjuvant treatment
In view of the high frequency of recurrences after surgery,
clinicians should consider in multidisciplinary discussions the
options of a neo-adjuvant or adjuvant therapy. A neo-adjuvant
or adjuvant treatment does not replace adequate surgery, which
remains the cornerstone of a therapeutic strategy with curative
intentions. In view of the decision of a (neo-) adjuvant therapy
adequate staging is important, the TNM classification (version
2002) should be used (Table 2). Identification of the risk of
recurrence and risk-benefit analysis of a (neo-) adjuvant
treatment should always be done.
Patterns of relapse are important when considering adjuvant
therapy. It has been shown that more than half of the patients
who undergo a resection with curative intention will have
locoregional recurrence [2]. This highlights the fact that surgery
alone was unable to eradicate all locoregional disease and
supports again the need for optimal surgery and also for the
evaluations of complementary strategies aiming at decreasing
local relapse as well as distant metastases.
Although the treatment delivered determines a patient’s
prognosis to a large extent, other factors, such as patient age and
gender, the stage of disease at presentation, tumour localisation
and morphology play a substantial role. Current staging
modalities, which solely focus on the extent of tumour invasion
and the presence of lymph node disease, do not take these
factors into account. Therefore nomograms have been
developed to address this problem. They are predictive tools for
the individual patient based on known prognostic variables
including the extent of surgical treatment. Nomograms help
with patient counselling, follow-up scheduling and clinical trial
determination and have been developed for several tumours.
Recently a statistical model developed for gastric carcinoma was
able to predict an individual patient’s probability for 5–9 year
disease specific survival after R0 resection for gastric cancer in
a single institution US population involving more than 1000
patients [21]. This nomogram has been validated in
a multicentre study of 459 patients from the Dutch Gastric
Cancer trial. The nomogram provided predictions that
discriminated better than the AJCC staging system, regardless of
the extent of lymph node dissection [22, 23].
adjuvant chemotherapy
Most of the individual trials studying the effect of postoperative
adjuvant chemotherapy do not show a survival advantage
compared to surgery alone. These studies often randomised
a low number of patients and are clearly underpowered. The
trials studied also predominantly older chemotherapy regimens,
although the most recently reported trials have used adequate
cisplatin-containing regimens [24]. Further, the patient
populations studied were heterogeneous, including patient
populations with both high and low risk of recurrence.
Five meta-analyses (or combined analyses) of adjuvant
chemotherapy have been published [25–29]. Most of the
analyses show a small benefit in survival for patients treated with
postoperative adjuvant chemotherapy. When analysed, this
small gain is only seen in Asian, and not in Western world,
studies. Because of the nature of the data adjuvant
chemotherapy is not generally advised to patients who undergo
a complete surgical resection of gastric cancer.
postoperative chemoradiotherapy
A very important study is the trial of the US GI-Intergroup
study, which randomised 556 patients with resected
adenocarcinoma of the stomach or gastro-oesophageal junction
to surgery plus postoperative chemoradiotherapy or surgery
alone [30]. The adjuvant treatment consisted of 425 mg/m2
5-FU (bolus infusion) per day plus 20 mg/m2 of leucovorin (LV)
Table 1. Surgery in gastric cancer
• Should be performed by
– well trained and experienced surgeons
– in centres of excellence
• Quality control of surgery is important
• Quality control of pathology is important
• Multidisciplinary approach and discussion is warranted
• Type of surgery
– Total gastrectomy for proximal tumours
– Subtotal gastrectomy for distal tumours
– Subtotal or distal oesophagectomy for distal oesophageal tumours
and GE junction tumour – Siewert type 1
– Endoscopic mucosal resection only for very superficial lesions
– Limited resection + sentinel node resection for T1 tumours:
adequate locoregional control and survival in experienced hands
• At least D1 resection
• Mandatory: at least 15 lymph nodes
• No routine sentinel lymph node analysis
• Free margins
• No splenectomy unless tumour extends to spleen.
World Congress on Gastrointestinal Cancer: Barcelona 2005 expert
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for five days, followed by 45 Gy in 25 fractions of 1.8 Gy over
5 weeks with bolus 5-FU and LV during the first and last week of
the radiotherapy. This was followed 4 weeks later by two cycles
of bolus 5-FU/LV. The median overall survival in the surgery
only arm was 27 months, compared to 36 months in the
chemoradiotherapy group (P < 0.05). The survival at 3 years was
50 versus 40% in favour of patients treated with postoperative
chemoradiotherapy. After a median follow-up of 5 years,
compared with surgery alone, the 5 year overall survival was
improved by 11.6% (28.4% versus 40% respectively; P < 0.001)
and the relapse-free survival was increased from 25 to 31% in
favour of patients treated with postoperative
chemoradiotherapy. Patients treated with postoperative
chemoradiotherapy had significantly fewer locoregional
recurrences. Three patients died from toxic effects of
chemoradiotherapy. Grade 3 toxic effects occurred in 41% and
grade 4 in 32% of the patients treated with chemoradiotherapy
[30]. Most patients did not undergo an extensive surgical
resection although the protocol recommended a D2 resection.
Fifty-four percent of the patients did not even have a D1
resection [24]. It has therefore been suggested that the
postoperative chemoradiotherapy was simply making up for
inadequate surgery. However, a large observational study from
Korea, while confirming the results of the US Intergroup study,
suggested also a benefit of postoperative chemoradiotherapy
after D2 resection [31]. It is, however, also possible that the
effects could have been even larger if surgery had been more
adequate leaving fewer cancer cells to be killed by the additional
therapy. The chemotherapy used in this study was never
considered to be a highly effective combination for stomach
cancer. Therefore better chemotherapeutic options should be
investigated in this setting: actually infused regimens of 5-FU are
recommended in this combination regimen because of better
tolerability. In gastric cancer, there are no trials having
compared bolus with infused 5-FU. The addition of new
cytotoxic agents is under investigation [32].
The experts at the World Congress on Gastrointestinal Cancer
recommend, however, to use a more optimised Intergroup
schedule. There was an agreement that infused 5-FU instead of
bolus 5-FU regimens before, during and after radiotherapy
should be recommended. There was an agreement that cisplatin
or irinotecan based chemotherapy before, during and after the
radiotherapy is reserved for evaluation in protocols.
The experts recommend irradiating similar volumes as those
irradiated in the Intergroup protocol. A dose of 45 Gy in
fractions of 1.8 Gy is recommended. Postoperative radiotherapy
in gastric cancer should be performed by experienced radiation
oncologists.
The target volume should be delineated on a CT scan in the
treatment position taking into account the surgery and
pathology reports. Up to 30% deviations from the treatment
protocol were noticed in the Intergroup study so careful
planning by experienced radiation oncologists is a prerequisite
[30, 33].
perioperative chemotherapy
The Magic trial compared a strategy of surgery alone with the
administration of three cycles of preoperative chemotherapy
followed by surgery followed by three cycles of postoperative
chemotherapy (perioperative chemotherapy) in 504 patients
with gastric and GE junction adenocarcinoma. The ECF
regimen was selected as chemotherapy regimen: epirubicin,
cisplatin and protracted 5-FU every 3 weeks. The patients
treated with perioperative chemotherapy had a significantly
better survival: 50 versus 41% were alive at 2 years and 36 versus
23% at 5 years compared to patients who were treated with
surgery only. The median survival was significantly longer for
patients treated with perioperative chemotherapy: 24 versus 20
months (P = 0.009). The progression free survival was also
significantly improved for patients treated with perioperative
chemotherapy: HR 0.66 (95% CI 0.53 – 0.81; P = 0.0001) [34].
Approximately 40 % of the patients enrolled in the experimental
Table 2. TNM classification [6]
Primary tumour (T)
TX: primary tumour cannot be assessed
T0: no evidence of primary tumour
Tis: carcinoma in situ: intraepithelial tumour without invasion of the lamina propria
T1: tumour invades lamina propria or submucosa
T2: tumour invades muscularis propria or subserosa
T2a: tumour invades muscularis propria
T2b: tumour invades subserosa
T3: tumour invades the serosa (visceral peritoneum) without invasion of adjacent structures
T4: tumour directly invades adjacent structures
Regional lymph nodes (N)
NX: regional lymph node(s) cannot be assessed
N0: no regional lymph node metastasis
N1: metastasis in one to six regional lymph nodes
N2: metastasis in 7–15 regional lymph nodes
N3: metastasis in more than 15 regional lymph nodes
Distant metastasis (M)
MX: presence of distant metastasis cannot be assessed
MO: no distant metastasis
M1: distant metastasis
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arm of the MAGIC trial did not receive the planned adjuvant
part of systemic therapy. This is in accordance with the observed
decreased patient tolerance to chemotherapy observed early
after gastrectomy which is probably related to poor food intake
capacity.
specific issues
Although phase II studies with preoperative chemoradiotherapy
for resectable tumours are appealing, this approach is at the
moment investigational. In T4 or ‘difficult’ tumours (especially
GE junction tumours) there is an emerging use of preoperative
chemoradiotherapy, based on the studies in oesophageal cancer
and on the phase II studies in gastric cancer.
The experts recognise the lack of specific studies in patients
with GE junction adenocarcinomas and recommend, because
most of the studies with gastric cancer include GE junction
adenocarcinomas as well, a treatment algorithm for patients
with GE junction tumours similar to patients with gastric
cancer.
In patients who underwent a partial gastrectomy and in
whom Helicobacter pylori was found, Helicobacter pylori
eradication in accordance with standard regimens, containing
a combination of a proton pomp inhibitor and a double of
antibiotics, is recommended, after recovery from surgery.
Intramuscular vitamin B12 injections should be administered
at regular intervals after gastrectomy.
general recommendations for treatment
The experts recognise the growing evidence that (neo-)adjuvant
treatment increases the outcome of selected patients. As general
strategy there was an agreement to recommend postoperative
chemoradiotherapy in patients who underwent inadequate
surgery or less than D1 resection. The strategy of either
postoperative chemoradiotherapy or perioperative
chemotherapy can be recommended as strategies in centres after
multidisciplinary team discussions. For both strategies the
evidence is based on data from a large well performed
randomized trial (level 2 evidence). The evidence supporting
postoperative chemotherapy is not so strong and is based on
several combined analyses (level 3 evidence or possibly level 1
evidence for no sufficient positive benefit of therapy). The
experts agree to recommend a perioperative chemotherapy
or postoperative chemoradiotherapy for patients who have
stage T3, T4 or N+ M0 gastric cancer. There was no general
agreement whether patients with stage T2bN0 should be
offered an adjuvant treatment. In this setting other factors
should be taken into consideration (e.g. factors presented in
Nomograms).
A neo-adjuvant or adjuvant treatment should be offered only
to fit patients without important comorbidities. Crucial in good
tolerance, especially for the postoperative chemoradiotherapy, is
the ability of the patient to have an adequate calorie intake
during the treatment. Adequate measures are therefore
necessary, with eventually the administration of enteral
nutrition (Table 3).
surveillance of gastric cancer
There is no clear evidence in the literature that systematic
follow-up is useful. A detection of recurrence usually does not
lead to curative therapeutic interventions. The purpose of
follow-up visits is for general symptom care. The experts
therefore recommend limiting technical examinations to
a minimum if the patient is asymptomatic. The frequency of
a surveillance visit is usually every 3–6 months in the first three
years and becomes less intensive after 3 years.
future research
There are still many open questions for future research:
• The evaluation of diagnostic modalities.
• The evaluation of prognostic and predictive markers.
• The evaluation of molecular characteristics.
• The evaluation of treatment strategies.
• The evaluation of new agents.
Table 3. (Neo-)adjuvant treatment in gastric cancer
• If inadequate surgery, i.e. <D1 resection: postoperative chemoradiotherapy should be considered
• Strategy of
– perioperative chemotherapy (pre- and postoperative) level 2 evidence (randomised controlled trial: Magic)
– postoperative chemoradiotherapy level 2 evidence (randomised controlled trial: INT-0116)
– postoperative chemotherapy level 3 evidence (not-optimal meta-analyses)
• Indication stage: (T2B), T3, T4 or N+ M0
• Adjuvant chemoradiotherapy
– optimised SWOG/INT schedule
• infused 5-FU before, during and after RT
• combination CT e.g. cisplatin/irinotecan in CRT are reserved for evaluation in clinical trials
– RT targets
• large targets similar to the SWOG/INT protocol
• 45 Gy in fractions of 1.8 Gy
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conclusions
Consensus cannot be reached on all aspects of the management
of gastric cancer, but expert advice can be given based on clinical
data and on clinical experience. The knowledge on gastric cancer
treatment is increasing and the evidence is growing that
‘optimal’ care improves the outcome of patients with gastric
cancer.
A multidisciplinary approach in experienced centres is
mandatory for adequate staging, for optimal surgery and for
the selection of an adequate (neo-)adjuvant strategy.
Relapses after gastric cancer are frequent. Recent data on the
(neo-)adjuvant therapy have changed clinical practice in
patients with gastric cancer at risk of recurrence after complete
gastric cancer resection. There is actually level 2 evidence for the
strategy of postoperative chemoradiotherapy and for the
strategy of perioperative, i.e. pre- and postoperative
chemotherapy and level 3 evidence for postoperative adjuvant
chemotherapy. The strategy of postoperative
chemoradiotherapy and of perioperative chemotherapy
decreases the risk of recurrence and improves the outcome for
patients fit to undergo these treatments.
Those involved in the treatment of patients with gastric
cancer should be encouraged to participate in well-designed
clinical trials, in order to increase the evidence-based knowledge
and to make further progress.
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